About Formosa Pharmaceuticals

Senior Management

Dr. CY Cheng founded Formosa Laboratories, Inc. in 1996, and Formosa Pharmaceuticals in 2010. He received his Ph.D. degree in Medicinal Chemistry from University of California, San Francisco, and conducted postdoctoral research at MIT. He has over 35 years’ pharmaceutical industrial experience including at DuPont in Delaware (United States). Just prior to his industrial engagements, Dr. Cheng was also a Professor in the College of Pharmacy at National Taiwan University.
Dr. Erick Co has over 20 years’ drug discovery experience leading to the invention of 6 preclinical and clinical drug candidates. He received a B.S. degree in Chemistry from the California Institute of Technology, and a Ph.D. in Synthetic Organic Chemistry from University of California, Los Angeles.Trained as a medicinal chemist in leading biotech and pharma companies such as Exelixis and Takeda, where he contributed to several clinical phase candidates, Erick transitioned into managerial roles at Nitto Denko and ScinoPharm Taiwan. He serves as Chief Executive Officer for Formosa Pharmaceuticals.
Ms. Lin joins Formosa Pharmaceuticals after more than 15 years as VP of Finance and Administration at Taiwan Liposome Company (TWSE 4152.TW) where she oversaw and guided TLC from pre-IPO stages through IPO filing, and SPOs, including dual listing of ADR in NASDAQ.  Prior to her appointment at TLC, she served as Accounting Manager at several California-based technology firms, and was also Securities Underwriter for Taiwan Securities.  Ms. Lin received her MBA from the University of California, Riverside, and recognized as a Certified Public Accountant in California, and a Qualified Accounting Supervisor by the Taiwan Securities Exchange Commission and Taipei Exchange.
Dr. Chen has over 15 years’ industry and academia experience in Food and Cosmetic sciences. Prior to joining Formosa Pharmaceuticals, he was a Professor at Vanung University in Taoyuan, Taiwan where he served as the Vice Chairman. Dr. Chen’s educational training includes a postdoctoral appointment at the National Health Research Institutes of Taiwan, and a Ph.D. in Food and Nutritional Sciences at the University of Shizuoka, Japan. Dr. Chen now heads the Nanotechnology division of Formosa Pharmaceuticals, developing APP13007, APP13002, and directing new research to expand the scope of the APNT formulation platform.
Ms. Tsan earned her B.S. in Zoology at National Taiwan University and M.S. in Toxicology at the University of Michigan. Upon returning to Taiwan she worked at several prominent R&D outsourcing and clinical management firms in Taipei. Kate now leads the Project Management team at Formosa Pharmaceuticals, overseeing the progress and development of all programs.

Development Pipeline

Scroll to Top